Due to the high incidence and demographic development, there is an urgent need for healthcare research data on lower urinary tract symptoms due to benign prostatic hyperplasia (LTUS/BPH). Since 2005 the Governing Body of German Prostate Centers (DVPZ) has been collecting data from 22 prostate centers in order to determine the quality and type of cross-sectoral care in particular for LUTS/BPH patients.
Presentation of the DVPZ database in general, as well as an investigation of treatment patterns for medical and instrumental therapies.
The analysis is based on UroCloud data sets from 30 November 2017. In the UroCloud data on diagnostics, therapy and course of disease are recorded in a web-based manner.
A total of 29,555 therapies were documented for 18,299 patients (1.6/patient), divided into 48.5% instrumental, 29.2% medical treatment, and 18.0% "wait and see" (in 4.3% no assignment was possible). Patients treated with an instrumental therapy were oldest (median: 72 years, interquartile range: 66-77), had the largest prostate volumes (50 ml, 35-75 ml), and were mostly bothered by symptoms (International Prostate Symptom Score = 19/4). The majority of patients under medical treatment received alphablockers (56%); phytotherapeutics were used least frequently (3%). Instrumental therapies are dominated by transurethral resection (TUR) of the prostate (60.0%), open prostatectomy (9.4%) and laser therapy (5.0%), with laser therapy having the shortest hospital stay (5 days) and the lowest transfusion and re-intervention rates (1.0% and 4.6%, respectively).
The DVPZ certificate covers the complete spectrum of cross-sectoral care for LUTS/BPH patients and documents the use of the various therapies as well as their application and effectiveness in the daily routine setting.
Der Urologe. Ausg. A. 2020 Apr 09 [Epub ahead of print]
J Herden, T Ebert, D Schlager, J Pretzer, J Zumbé, H-J Sommerfeld, W Schafhauser, M Kriegmair, M Garcia Schürmann, F Distler, H Baur, F Oberpenning, M Reimann, S Schmidt, S Laabs, B Planz, E Gronau, G Platz, A Göll, S Buse, J Jones, G Haupt, M Waldner, A Heidenreich, E Khaljani, H Rübben, W Schultze-Seemann, P Weib
Dachverband der Prostatazentren Deutschlands e. V., Berlin, Deutschland. ., Dachverband der Prostatazentren Deutschlands e. V., Berlin, Deutschland., Prostatazentrum Freiburg, Freiburg, Deutschland., Berliner Prostatazentrum, Berlin, Deutschland., Prostatazentrum Marl, Marl, Deutschland., Prostatazentrum Hochfranken-Fichtelgebirge, Marktredwitz, Deutschland., Prostatazentrum Urologie Centrum München, Planegg, Deutschland., Prostatazentrum Niederrhein, Wesel, Deutschland., Prostatazentrum Nürnberg-Mittelfranken, Nürnberg, Deutschland., Prostatazentrum Nymphenburg, München, Deutschland., Prostatazentrum Bocholt, Bocholt, Deutschland., Prostatazentrum Moers, Moers, Deutschland., Prostatazentrum Rhein-Ruhr, Oberhausen, Deutschland., Prostatazentrum Elbe-Weser, Stade, Deutschland., Prostatazentrum Emscher-Lippe, Gladbeck, Deutschland., Prostatazentrum Münsterland, Münster, Deutschland., Prostatazentrum Mainspitze, Rüsselsheim, Deutschland., Prostatazentrum Alfred Krupp Krankenhaus, Essen, Deutschland., Prostatazentrum Hochtaunus, Bad Homburg, Deutschland., Prostatazentrum Speyer, Speyer, Deutschland., Prostatazentrum Köln, Campus Hohenlind, Köln, Deutschland., Prostatazentrum Köln, Campus Universitätsklinikum, Kerpener Str. 62, 50937, Köln, Deutschland.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/32274545